Early research (Phase 1)Study completedNCT04338724What this trial is testingA Phase I Study of CS1002 in Subjects With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor CStone Pharmaceuticals 6
Early research (Phase 1)Active Not RecruitingNCT02879695What this trial is testingBlinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaWho this might be right forRecurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more National Cancer Institute (NCI) 28
Testing effectiveness (Phase 2)Ended earlyNCT03894215What this trial is testingRaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerWho this might be right forCervical Cancer Agenus Inc. 211
Testing effectiveness (Phase 2)Looking for participantsNCT05187338What this trial is testingTriplex Checkpoint Inhibitors Therapy for Advanced Solid TumorsWho this might be right forLung CancerLiver CancerColorectal Cancer+8 more Second Affiliated Hospital of Guangzhou Medical University 100
Not applicableStudy completedNCT04253080What this trial is testingExpression of IL4 Induced Gene 1 in Patients With Cutaneous Melanoma: Value in Prognosis and/or in Predictive Response to Immune Checkpoint InhibitorsWho this might be right forCutaneous Melanoma Assistance Publique - Hôpitaux de Paris 127
Testing effectiveness (Phase 2)WithdrawnNCT03982173What this trial is testingBasket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid TumorsWho this might be right forMetastatic Colorectal CancerTriple Negative Breast CancerProstate Adenocarcinoma+2 more Gustave Roussy, Cancer Campus, Grand Paris
Testing effectiveness (Phase 2)Looking for participantsNCT06967103What this trial is testingQL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast CancerWho this might be right forBreast CancerHR+/HER2- Breast Cancer Henan Cancer Hospital 238
Testing effectiveness (Phase 2)Looking for participantsNCT07232654What this trial is testingIparomlimab/Tuvonralimab Injection Plus CCRT in LACCWho this might be right forLOCALLY ADVANCED CERVICAL CANCERS Cancer Institute and Hospital, Chinese Academy of Medical Sciences 30
Testing effectiveness (Phase 2)Ended earlyNCT06173505What this trial is testingStudy of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCWho this might be right forNonsquamous Non-small Cell Lung Cancer Xencor, Inc. 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07515469What this trial is testingA Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence RiskWho this might be right forHCC - Hepatocellular CarcinomaIparomlimab and Tuvonralimab InjectionNeoadjuvant Immunotherapy Tianjin Medical University Cancer Institute and Hospital 30
Testing effectiveness (Phase 2)Looking for participantsNCT06741644What this trial is testingA Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumors CStone Pharmaceuticals 800
Testing effectiveness (Phase 2)Active Not RecruitingNCT06508606What this trial is testingAK117 (Anti-CD47 mAb) Plus Cetuximab or AK104 (Anti-PD-1/CTLA-4 bsAb) as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaWho this might be right forHead and Neck Squamous Cell Carcinoma West China Hospital 20
Early research (Phase 1)Active Not RecruitingNCT05631899What this trial is testingCAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid TumorsWho this might be right forSolid Tumor, AdultEphA2 OverexpressionKRAS G12V+2 more Chinese PLA General Hospital 9
Testing effectiveness (Phase 2)Study completedNCT04225390What this trial is testingPreconditioning of Tumor, Tumor Microenvironment and the Immune System to ImmunotherapyWho this might be right forImmunotherapy University of Erlangen-Nürnberg Medical School 38
Testing effectiveness (Phase 2)Active Not RecruitingNCT04556253What this trial is testingAK104 in Locally Advanced MSI-H/dMMR Gastric Carcinoma and Colorectal CancerWho this might be right forMSI-H/dMMR Gastric Carcinoma and Colorectal Cancer Peking University 47
Testing effectiveness (Phase 2)Study completedNCT03249142What this trial is testingImmunotherapy With Neo-adjuvant Chemotherapy for OVarian CancerWho this might be right forOvarian Cancer ARCAGY/ GINECO GROUP 69
Testing effectiveness (Phase 2)Study completedNCT01896869What this trial is testingFOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic CancerWho this might be right forMetastatic Pancreatic Adenocarcinoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 83
Very early researchActive Not RecruitingNCT02812420What this trial is testingDurvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before SurgeryWho this might be right forHydronephrosisInfiltrating Bladder Urothelial Carcinoma Sarcomatoid VariantInfiltrating Bladder Urothelial Carcinoma, Micropapillary Variant+16 more M.D. Anderson Cancer Center 54
Early research (Phase 1)Not Yet RecruitingNCT07619001What this trial is testingEvaluate the PK Similarity of AK104 in Healthy Chinese Male ParticipationsWho this might be right forHealthy Male Adults Participants Akeso 158
Testing effectiveness (Phase 2)WithdrawnNCT04007588What this trial is testingA Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV MelanomaWho this might be right forMelanoma Stage IIIMelanoma Stage IV Dana-Farber Cancer Institute